Recruiting
Hormone-dependent prostate cancer
RecruitingRegistered drugNo placebo
A study to evaluate the effects of lutetium (177lu) vipivotide tetraxetan in patients with metastatic hormone sensitive prostate cancer receiving androgen deprivation therapy.
Registered drugNo placebo
- Disease:Hormone-dependent prostate cancer
- Substances:Lutetium (177Lu) Vipivotide Tetraxetan
Countries:
Ireland
Ireland- Participants:18–64 years · 65+ years
- Substances:Lutetium (177Lu) Vipivotide Tetraxetan
- Sponsor:University College London


